Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection

Batty, Cole J.; Heise, Mark T.; Bachelder, Eric M.; Ainslie, Kristy M.

doi:10.1016/j.addr.2020.12.006

Cited by 67 publications

(63 citation statements)

References 213 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This has led to over 20 vaccine candidates in clinical trials and over 140 more in preclinical evaluation, made by almost as many developers. [25,141] Vaccines developed for a pandemic seem to be an exception for otherwise low profitability, as $3.3 billion in sales accompanied vaccines made in 2009 during the H1N1 influenza pandemic. [142] A first-to-market vaccine can carry the advantage of gaining the largest contracts, which was seen with Novartis' H1N1 influenza vaccine in the US during the 2009 pandemic.…”

Section: Yesmentioning

confidence: 99%

“…Several particle-based vaccines for COVID-19, such as lipid complexes and VLPs, are also in development. [25,141] Whether the current pandemic environment will garner advances for polymeric particle vaccines is still yet to be determined.…”

Section: Yesmentioning

confidence: 99%

“…Indeed, the two leading vaccine candidates for the COVID-19 pandemic, developed by Moderna and Pfizer/BioNTech, are a lipid nanoparticle (NP) that complexes mRNA encoding the SARS-CoV-2 spike protein. [23][24][25] If approved, COVID-19-based vaccines would be the first nucleic acid vaccines to be approved by the FDA. At the time of writing this review, Pfizer/BioNTech has been approved for application in the United Kingdom [26] and Moderna has filed for emergency FDA approval of their vaccine.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Considerations for Size, Surface Charge, Polymer Degradation, Co‐Delivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases

Genito

Batty

Bachelder

et al. 2021

Advanced NanoBiomed Research

Self Cite

View full text Add to dashboard Cite

Vaccines have advanced human health for centuries. To improve upon the efficacy of subunit vaccines they have been formulated into nano/microparticles for infectious diseases. Much progress in the field of polymeric particles for vaccine formulation has been made since the push for a tetanus vaccine in the 1990s. Modulation of particle properties such as size, surface charge, degradation rate, and the co‐delivery of antigen and adjuvant has been used. This review focuses on advances in the understanding of how these properties influence immune responses to injectable polymeric particle vaccines. Consideration is also given to how endotoxin, route of administration, and other factors influence conclusions that can be made. Current manufacturing techniques involved in preserving vaccine efficacy and scale‐up are discussed, as well as those for progressing polymeric particle vaccines toward commercialization. Consideration of all these factors should aid the continued development of efficacious and marketable polymeric particle vaccines.

show abstract

Section: Yesmentioning

confidence: 99%

Section: Yesmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Considerations for Size, Surface Charge, Polymer Degradation, Co‐Delivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases

Genito

Batty

Bachelder

et al. 2021

Advanced NanoBiomed Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Unlike traditional vaccines, a synthetically created RNA sequence of virus fragments encoding the S protein is injected. The mRNA fragment is placed in the lipid nanoparticle (LNP) vehicle which prevents degradation by the host until it is taken by the cell [ 15 ]. The mRNA strand does not enter the nucleus of the cell.…”

Section: Messenger Rna (Mrna)-based Vaccines: Pfizer-biontech and Modernamentioning

confidence: 99%

Review of COVID-19 Vaccines Approved in the United States of America for Emergency Use

Vasireddy¹,

Atluri

Malayala

et al. 2021

J Clin Med Res

View full text Add to dashboard Cite

“…However, mRNA delivery therapy in vivo has been considered a major bottleneck. Recent studies have shown that the incorporation of therapeutic mRNA nanoparticles can overcome in vivo delivery problems, such as the insufficient expression of intracellular proteins, and the deficient antigen loading, as well as the maturation of antigen-presenting cells [ 125 ]. In 1994, the group of Curiel et al was the first to evaluate the effect of mRNAs on the in vivo delivery of liposomes and demonstrated that the expression of the mRNAs-cationic liposome complex was comparable to the corresponding pDNA complex when injected into tumors [ 126 ].…”

Section: Nanoparticle-based Drug Delivery For Melanoma Therapeuticmentioning

confidence: 99%

Nanocarrier-Based Drug Delivery for Melanoma Therapeutics

Song

Liu

Chen

et al. 2021

IJMS

View full text Add to dashboard Cite

Melanoma, as a tumor cell derived from melanocyte transformation, has the characteristics of malignant proliferation, high metastasis, rapid recurrence, and a low survival rate. Traditional therapy has many shortcomings, including drug side effects and poor patient compliance, and so on. Therefore, the development of an effective treatment is necessary. Currently, nanotechnologies are a promising oncology treatment strategy because of their ability to effectively deliver drugs and other bioactive molecules to targeted tissues with low toxicity, thereby improving the clinical efficacy of cancer therapy. In this review, the application of nanotechnology in the treatment of melanoma is reviewed and discussed. First, the pathogenesis and molecular targets of melanoma are elucidated, and the current clinical treatment strategies and deficiencies of melanoma are then introduced. Following this, we discuss the main features of developing efficient nanosystems and introduce the latest reports in the literature on nanoparticles for the treatment of melanoma. Subsequently, we review and discuss the application of nanoparticles in chemotherapeutic agents, immunotherapy, mRNA vaccines, and photothermal therapy, as well as the potential of nanotechnology in the early diagnosis of melanoma.

show abstract

Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection

Cited by 67 publications

References 213 publications

Considerations for Size, Surface Charge, Polymer Degradation, Co‐Delivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases

Considerations for Size, Surface Charge, Polymer Degradation, Co‐Delivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases

Review of COVID-19 Vaccines Approved in the United States of America for Emergency Use

Nanocarrier-Based Drug Delivery for Melanoma Therapeutics

Contact Info

Product

Resources

About